IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

AGENO, WALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 57.716
EU - Europa 25.579
AS - Asia 18.729
SA - Sud America 2.137
Continente sconosciuto - Info sul continente non disponibili 951
AF - Africa 344
OC - Oceania 27
Totale 105.483
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 57.064
IT - Italia 11.942
SG - Singapore 6.111
UA - Ucraina 4.102
CN - Cina 3.803
TR - Turchia 2.851
VN - Vietnam 2.492
HK - Hong Kong 2.171
SE - Svezia 1.875
DE - Germania 1.858
BR - Brasile 1.763
IE - Irlanda 1.239
GB - Regno Unito 1.035
FR - Francia 1.002
FI - Finlandia 975
RU - Federazione Russa 861
BD - Bangladesh 303
IN - India 293
CA - Canada 275
MX - Messico 240
AR - Argentina 124
NL - Olanda 118
JP - Giappone 115
AT - Austria 108
NG - Nigeria 98
ES - Italia 96
IQ - Iraq 95
PL - Polonia 92
ZA - Sudafrica 83
EC - Ecuador 62
ID - Indonesia 60
EU - Europa 53
PK - Pakistan 52
SA - Arabia Saudita 51
CO - Colombia 50
BE - Belgio 48
MY - Malesia 39
UZ - Uzbekistan 39
VE - Venezuela 39
AE - Emirati Arabi Uniti 37
CZ - Repubblica Ceca 35
JM - Giamaica 35
MA - Marocco 34
CL - Cile 30
LT - Lituania 30
CR - Costa Rica 26
EG - Egitto 24
PH - Filippine 24
JO - Giordania 23
KE - Kenya 23
PY - Paraguay 23
AU - Australia 21
CH - Svizzera 21
DZ - Algeria 19
RO - Romania 19
NP - Nepal 18
MD - Moldavia 17
TN - Tunisia 17
PT - Portogallo 16
TW - Taiwan 16
BO - Bolivia 15
IR - Iran 15
UY - Uruguay 15
PE - Perù 14
GR - Grecia 12
GT - Guatemala 12
KR - Corea 12
KZ - Kazakistan 12
TT - Trinidad e Tobago 12
AL - Albania 11
IL - Israele 11
HN - Honduras 10
HU - Ungheria 9
LB - Libano 9
PS - Palestinian Territory 9
TH - Thailandia 9
NI - Nicaragua 8
OM - Oman 8
SN - Senegal 8
AZ - Azerbaigian 7
CI - Costa d'Avorio 7
DK - Danimarca 7
MK - Macedonia 7
NO - Norvegia 7
BA - Bosnia-Erzegovina 6
BG - Bulgaria 6
DO - Repubblica Dominicana 6
QA - Qatar 6
RS - Serbia 6
AM - Armenia 5
ET - Etiopia 5
NZ - Nuova Zelanda 5
SV - El Salvador 5
AO - Angola 4
BB - Barbados 4
BS - Bahamas 4
CG - Congo 4
GE - Georgia 4
HR - Croazia 4
KH - Cambogia 4
Totale 104.509
Salva come PNG Salva come JPEG
Città #
Milan 8.538
Fairfield 7.198
Woodbridge 4.800
Ashburn 4.711
San Jose 3.882
Houston 3.570
Jacksonville 3.306
Singapore 3.206
Seattle 2.807
Wilmington 2.632
Cambridge 2.460
Ann Arbor 2.425
Chandler 2.237
Hong Kong 2.137
Dallas 1.577
Izmir 1.397
Princeton 1.351
Dublin 1.229
Council Bluffs 1.175
The Dalles 985
Dearborn 961
Boardman 833
Beijing 700
Dong Ket 683
Nyköping 664
Rome 652
Chicago 646
Lauterbourg 639
San Diego 401
Ho Chi Minh City 400
Los Angeles 364
New York 346
Santa Clara 345
San Mateo 308
Ogden 262
London 260
Hanoi 246
Helsinki 228
Como 190
Guangzhou 184
São Paulo 180
Washington 174
Mexico City 153
Munich 153
Düsseldorf 139
Orem 135
Hefei 129
Redmond 122
Nanjing 106
Nuremberg 98
Tokyo 97
Shanghai 93
Abuja 92
Phoenix 92
Frankfurt am Main 90
Kocaeli 88
Verona 85
Kunming 84
Chennai 83
Norwalk 77
Hangzhou 76
Warsaw 75
Brooklyn 74
Montreal 74
Salt Lake City 72
San Francisco 71
Buffalo 68
Tianjin 64
Shenzhen 62
Atlanta 61
Toronto 60
Amsterdam 59
Columbus 59
Nanchang 59
Stockholm 59
Jinan 58
Denver 57
Haiphong 57
Boston 56
Turku 55
Rio de Janeiro 54
Da Nang 53
Philadelphia 53
Manchester 52
Tampa 50
Belo Horizonte 46
Elk Grove Village 46
Johannesburg 46
Zhengzhou 46
Vienna 44
Brussels 39
Kilburn 39
Falls Church 38
Fuzhou 35
Tashkent 34
Besana In Brianza 33
Curitiba 33
Miami 33
Changsha 32
Mumbai 32
Totale 75.319
Salva come PNG Salva come JPEG
Nome #
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts 406
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 314
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 313
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 310
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 308
Warfarin interactions with antibiotics in the ambulatory care setting 297
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 295
Abdominal obesity and the risk of recurrent deep vein thrombosis 276
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 275
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 273
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 270
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 269
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 268
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 264
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 264
ABO blood group and vascular disease: an update 261
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 260
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 259
Risk of recurrence of unusual site venous thromboembolism 259
Optimal treatment duration of venous thrombosis 253
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 250
Management of recurrent venous thromboembolism in cancer patients 249
Breadth of complications of long-term oral anticoagulant care 247
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 245
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 240
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 240
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 236
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 234
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 234
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 233
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 233
Prevention and treatment of venous thromboembolism 232
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 232
A new era for venous thromboembolism prevention in medical inpatients 232
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 231
Exaggerated initial response to warfarin following heart valve replacement 231
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 231
Venous ischemic syndromes 231
Oral rivaroxaban for symptomatic venous thromboembolism 229
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 228
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 228
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment 226
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 226
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 225
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 225
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 224
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 224
Patient selection for thromboprophylaxis in medical inpatients 224
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 222
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 221
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 221
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 220
Applying EBM in clinical practice 219
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 219
Abdominal obesity and the risk of recurrent deep vein thrombosis. 218
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. 218
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 218
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 217
Venous and arterial thrombosis in patients with HIV infection 216
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 216
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 216
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 216
Statins, fibrates, and venous thromboembolism: a meta-analysis. 215
Duration of anticoagulation after venous thromboembolism in real world clinical practice 215
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 214
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 214
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 213
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 213
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 211
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 211
Venous thromboembolism: Past, present and future 211
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 211
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 211
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 210
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality 209
A survey of thromboprophylaxis management in patients with major trauma. 209
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 209
Management of incidental splanchnic vein thrombosis in cancer patients 209
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 209
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 209
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 208
Direct oral anticoagulants in rare venous thrombosis 208
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study 208
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 207
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 207
Guidance for the management of venous thrombosis in unusual sites 207
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial 207
Managing challenging patients with venous thromboembolism: A practical, case-based approach 206
Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants 205
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 205
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 205
Treating patients with cancer and acute venous thromboembolism 204
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) 204
Dabigatran in clinical practice: Contemporary overview of the evidence 203
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation 202
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 201
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis 201
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 201
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. 200
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 200
Totale 23.163
Salva come PNG Salva come JPEG
Categoria #
all - tutte 452.986
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 452.986
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.071 0 872 355 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20259.742 69 75 1.781 238 230 684 403 654 1.099 820 967 2.722
2025/202623.376 1.428 1.409 1.478 2.721 1.762 1.425 5.181 1.401 2.969 1.581 1.099 922
2026/20271.764 625 1.139 0 0 0 0 0 0 0 0 0 0
Totale 105.483